Antibacterial activity of schiff base ligands containing pyridine and disulphide moieties against human bacterial pathogens
Version: 1,
Uploaded by: Administrator,
Date Uploaded:
27 November 2022
Warning
You are about to be redirected to a website not operated by the Mauritius Research and Innovation Council. Kindly note that we are not responsible for the availability or content of the linked site. Are you sure you want to leave this page?
To evaluate the antibacterial activities of N, N’[1, 1’-dithiobis (phenylene)] bis (benzyldeneimine), referred to as L1, and o, o’-(N, N-dipicolinyldene) diazadiphenyldisulfide, referred to as L2, containing disulfide moieties against some ophthalmic pathogens (Klebsiella sp., Escherichia coli, Streptococcus sp., Proteus morganii, Pseudomonas sp., Streptococcus pneumoniae, Acinetobacter sp., Streptococcus pyogenes and Streptococcus viridins,) urinary tract infectious pathogens (Proteus morganii, Escherichia coli, Pseudomonas sp. Enterobacter sp. Klebsiella sp) and antibiotic resistant pathogens (Staphylococcus sp., Streptococcus, Pseudomonas sp. Klebsiella sp.) for minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The minimum inhibitory concentration (MIC) for the ophthalmic pathogens and antibiotic resistant pathogens were found to be 400-500 µg/ml while for the urinary tract infectious pathogens a lower MIC value (200 µg/ml) was obtained. The minimum bactericidal concentration for the compounds against all the pathogens tested was 400-500 µg/ml. The synthesized schiff L1 and L2 were showed the MIC values for all the tested ophthalmic and antibiotic resistant bacterial pathogens more or less similar. Further studies are needed to prove the safe and efficacy of needed for these compounds to develop as a drug after completing successful preclinical and clinical tests.
